News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cynosure, Inc. (CYNO) to Present at Canaccord Genuity Medical Technology & Diagnostics Forum



11/27/2012 9:39:53 AM

WESTFORD, Mass., Nov. 27, 2012 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO), a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced that its senior management will present at the Canaccord Genuity Medical Technology & Diagnostics Forum at 10:30 a.m. (ET) on Tuesday, December 4 in New York City.

The presentation by Cynosure President and CEO Michael Davin and Executive Vice President, Treasurer and CFO Timothy Baker will be available via live and archived audio webcast accessible through a link on the Investor Relations section of the Company's website, www.cynosure.com.

About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, remove multi-colored tattoos, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite and treat onychomycosis. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Q-switched, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.

Contact:

Scott Solomon
Vice President
Sharon Merrill Associates, Inc.
617.542.5300
cyno@investorrelations.com

SOURCE Cynosure, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES